NeuroSense Therapeutics (NRSN) Long-Term Investments (2022 - 2025)
NeuroSense Therapeutics (NRSN) posted Long-Term Investments of $22000.0 for Q4 2025, down 48.84% sequentially from $43000.0 in Q2 2025, and down 4.35% YoY from $23000.0 in Q4 2024.
NeuroSense Therapeutics (NRSN) Long-Term Investments (2022 - 2025) Analysis & Trends
NeuroSense Therapeutics has reported Long-Term Investments for 4 years, with the latest figure at $22000.0 in Q4 2025.
- Quarterly Long-Term Investments fell 4.35% year-over-year to $22000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22000.0 (down 4.35% YoY) and the FY2025 annual result came in at $22000.0, down 4.35% from the prior year.
- Long-Term Investments declined to $22000.0 in Q4 2025 per NRSN's latest filing, from $43000.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $38.0 million in Q2 2023 and troughed at -$19000.0 in Q2 2022.
- A 4-year average of $3.5 million and a median of $35000.0 in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2023 and 2024: Long-Term Investments surged 200100.0% in 2023, then sank 99.91% in 2024.
- Over 4 years, Long-Term Investments stood at $23000.0 in 2022, then fell by 4.35% to $22000.0 in 2023, then increased by 4.55% to $23000.0 in 2024, then fell by 4.35% to $22000.0 in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $22000.0, $43000.0, and $23000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | 22,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Dec 31, 2023 | 22,000.00 |
| Sep 30, 2023 | 37,000.00 |
| Jun 30, 2023 | 38.00 Mn |
| Dec 31, 2022 | 23,000.00 |
| Jun 30, 2022 | -19,000.00 |